Life
Replimune's Skin Cancer Drug Faces Another FDA Rejection
Replimune's cancer drug candidate has been rejected by the FDA for the second time, raising questions and discussions within the medical community.
editorial-staff
1 min read
Updated about 15 hours ago
Summary
Replimune's drug candidate has once again failed to gain approval from the FDA, marking its second rejection in the review process.
This decision follows a contentious initial review that had already placed the drug under significant scrutiny.
The repeated rejection has ignited further debate among medical professionals regarding the drug's potential and the FDA's evaluation process.
Key Facts
| Fact | Value |
|---|---|
| Drug Name | Replimune |
| FDA Decision | Rejected |
| Initial Review Date | 2026-04-10 |
Updates
- No subsequent updates recorded.